Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Sulfonylurea (SU) Monotherapy: A CANVAS Substudy

被引：0
|
作者：
Fulcher, Greg
Matthews, David
Perkovic, Vlado
Mahaffey, Kenneth W.
Weiss, Robert
Rosenstock, Julio
Capuano, George
Desai, Mehul
Shaw, Wayne
Vercruysse, Frank
Meininger, Gary
Neal, Bruce
机构：
来源：
DIABETES | 2013年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1124-P
引用
收藏
页码：A292 / A292
页数：1
相关论文
共 50 条
  • [31] Efficacy and tolerability of vildagliptin added to a sulfonylurea (SU) in patients with type 2 diabetes (T2DM)
    Garber, A. J.
    Camisasca, R.-P.
    Jauffret, S.
    Baron, M. A.
    DIABETES, 2007, 56 : A134 - A134
  • [32] BAYESIAN NETWORK META-ANALYSIS TO ASSESS RELATIVE EFFICACY AND SAFETY OF CANAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED WITH METFORMIN
    Pacou, M.
    Taieb, V
    Abrams, K. R.
    Diels, J.
    van Sanden, S.
    Garg, M.
    Schroeder, M.
    Kaur, V
    Nielsen, A. T. N.
    Nuhoho, S.
    Neslusan, C.
    Hemels, M.
    VALUE IN HEALTH, 2013, 16 (07) : A609 - A609
  • [33] Long-term Efficacy and Safety of Canagliflozin (CANA) in Older Patients with Type 2 Diabetes Mellitus (T2DM) Over 104 Weeks
    Bode, Bruce
    Stenlof, Kaj
    Harris, Stewart
    Sullivan, Daniel
    Fung, Albert
    Usiskin, Keith
    DIABETES, 2014, 63 : A71 - A71
  • [34] Comparison of Treatment With Sitagliptin (SITA) or Sulfonylurea (SU) in Patients With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Insufficiency
    Engel, Samuel S.
    Xu, Lei
    Golm, Gregory T.
    O'Neill, Edward A.
    Kaufman, Keith D.
    Goldstein, Barry J.
    DIABETES, 2013, 62 : A139 - A139
  • [35] THE IMPACT OF ALTERNATIVE ESTIMATES OF DISUTILITIESASSOCIATED WITH HYPOGLYCEMIA ON NET QALYS: CANAGLIFLOZIN VERSUS SITAGLIPTIN AS ADD-ON THERAPY IN INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED ON A BACKGROUND OF METFORMIN (MET) PLUS SULFONYLUREA (SU) IN THE CANADIAN SETTING
    Yoong, K.
    Willis, M.
    Johansen, P.
    Yim, C.
    Teschemaker, A.
    Neslusan, C.
    VALUE IN HEALTH, 2014, 17 (03) : A190 - A190
  • [36] Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV
    Krzysztof Strojek
    A. Shekhar Pandey
    Vanessa Dell
    Melanie Sisson
    Shuai Wang
    Susan Huyck
    Jie Liu
    Ira Gantz
    Diabetes Therapy, 2021, 12 : 1175 - 1192
  • [37] Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV
    Strojek, Krzysztof
    Pandey, A. Shekhar
    Dell, Vanessa
    Sisson, Melanie
    Wang, Shuai
    Huyck, Susan
    Liu, Jie
    Gantz, Ira
    DIABETES THERAPY, 2021, 12 (04) : 1175 - 1192
  • [38] TIME UNTIL INSULIN INITIATION FOR CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN DUAL AND TRIPLE THERAPY FOR TYPE 2 DIABETES MELLITUS (T2DM) IN IRELAND
    Bacon, T.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    VALUE IN HEALTH, 2015, 18 (03) : A55 - A55
  • [39] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SAXAGLIPTIN (SAXA) AMONG OLDER INDIVIDUALS LIVING WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CANADA
    Teschemaker, A. R.
    Neslusan, C.
    Sabapathy, S.
    Yoong, K.
    Johansen, P.
    Willis, M.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A63
  • [40] ACHIEVEMENT OF GLYCAEMIC TARGETS WITH CANAGLIFLOZIN IN TRIPLE THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Diels, J.
    Schubert, A.
    Hamilton, G.
    Canovatchel, W.
    VALUE IN HEALTH, 2015, 18 (07) : A598 - A598
12345